Navigation Links
ENDECE Neural to Present Findings at 2013 Biotech Showcase on NDC-1308 which Induces Remyelination of Demyelinated Axons
Date:12/10/2012

MEQUON, Wis., Dec. 10, 2012 /PRNewswire/ -- ENDECE Neural, LLC (www.endeceneural.com) announced today that the company will be presenting at the 2013 Biotech Showcase in San Francisco, California, January 8th.

The ENDECE Neural presentation, to be given by Dr. James Yarger, CEO, will discuss the company's novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS).

Currently there are no drugs commercially available for remyelination in MS, or any other disease associated with demyelination. ENDECE Neural may have one of the first compounds with the ability to directly induce remyelination.

"This novel therapeutic could be used either alone or in combination with current immunosuppressant/anti-inflammation therapies," says Dr. Yarger. "We are looking to partner with or license this exciting opportunity to potentially restore function, mobility and independence to those fighting MS." 

About ENDECE Neural, LLC (an ENDECE Company)
ENDECE Neural is the wholly owned subsidiary of ENDECE, LLC. ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerve axons, and potentially restoring muscle control, mobility and independence to the lives of Multiple Sclerosis patients. ENDECE Neural maintains an exclusive license for the IP from its parent company.

About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fifth year, Biotech Showcase (www.ebdgroup.com/bts) features corporate presentations by 195 innovative life science companies to public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.


'/>"/>
SOURCE ENDECE Neural, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
2. Neural implant recovers ability to make decisions
3. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
4. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
5. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
6. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
7. Triangles guide the way for live neural circuits in a dish
8. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
9. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
10. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
11. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017  Former NFL players who had ... functions later in life, according to a preliminary study released ... Neurology,s 69th Annual Meeting in Boston , ... are complex movements where the muscles and nerves work together, ... ...
(Date:2/18/2017)... Arlington Heights, IL (PRWEB) , ... February 17, ... ... Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood ... Gaylord Palms Convention Center in Orlando, Fla. , The combined scientific ...
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... to find a better treatment for triple negative breast cancer ... France program. The YEi ... accelerator designed to help entrepreneurs grow their business in ... of eight American companies selected to complete an intensive one ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):